骨髓增殖性肿瘤患者感染风险——一项基于人群的8363例患者队列研究
该研究基于瑞典1992-2013年高质量登记数据,纳入8363例骨髓增殖性肿瘤(MPN)患者和32405例对照,随访至2015年。MPN患者任何感染的风险比为2.0(95%CI 1.9-2.0),脓毒症风险比为2.6(2.4-2.9),原发性骨髓纤维化患者任何感染风险比最高,为3.7(3.2-4.1)。2006-2013年间,未治疗患者与接受羟基脲或干扰素-α治疗的患者之间感染风险无显著差异。
要点
- MPN患者任何感染风险比为2.0(95%CI 1.9-2.0),细菌感染为1.9(1.8-2.0),病毒感染为2.1(1.9-2.3)。
- 脓毒症风险比为2.6(2.4-2.9),为风险增加最大的感染类型之一。
- 原发性骨髓纤维化任何感染风险比为3.7(3.2-4.1),真性红细胞增多症为1.7(1.6-1.8),原发性血小板增多症为1.7(1.5-1.8)。
核心结论
- MPN患者总体感染风险增加,且不随常用细胞减灭治疗而改变,提示感染风险增加是MPN本身固有的。
研究设计与样本
- 在瑞典开展的大型基于人群的匹配队列研究,纳入8363例MPN患者和32405例对照,使用高质量登记数据,时间范围为1992-2013年,随访至2015年。
主要发现
- 任何感染的风险比为2.0(95%CI 1.9-2.0),细菌感染为1.9(1.8-2.0),病毒感染为2.1(1.9-2.3)。
- 脓毒症的风险比为2.6(2.4-2.9)。
- 任何感染的风险比在原发性骨髓纤维化中最高,为3.7(3.2-4.1),在所有MPN亚型中均显著升高;真性红细胞增多症为1.7(1.6-1.8),原发性血小板增多症为1.7(1.5-1.8)。
- 2006-2013年间,未治疗患者与接受羟基脲或干扰素-α治疗的患者之间感染风险无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infections are a common complication in patients with many hematologic malignancies, however, whether patients with myeloproliferative neoplasms (MPN) also are at an increased risk of infections is largely unknown. To assess the risk of serious infections, we performed a large population-based matched cohort study in Sweden including 8 363 MPN patients and 32,405 controls using high-quality registers between the years 1992-2013 with follow-up until 2015. The hazard ratio (HR) of any infection was 2.0 (95% confidence interval 1.9-2.0), of bacterial infections 1.9 (1.8-2.0), and of viral infections 2.1 (1.9-2.3). One of the largest risk increases was that of sepsis, HR 2.6 (2.4-2.9). The HR of any infection was highest in primary myelofibrosis 3.7 (3.2-4.1), and significantly elevated in all MPN subtypes; 1.7 (1.6-1.8) in polycythemia vera and 1.7 (1.5-1.8) in essential thrombocythemia. There was no significant difference in risk of infections between untreated patients and patients treated with hydroxyurea or interferon-α during the years 2006-2013. These novel findings of an overall increased risk of infections in MPN patients, irrespective of common cytoreductive treatments, suggest the increased risk of infection is inherent to the MPN.
引用
- Landtblom AR, Andersson TM, Dickman PW, et al. Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients. Leukemia. 2020. PMID: 32546727. doi:10.1038/s41375-020-0909-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。